Keywords: genset, faces, decisions, over, antiobesity, agent, french

Genset faces decisions over antiobesity agent

Article | 25 July 2000

Print This

French genomics company Genset is facing crucial decisions over famoxin,a recombinant protein in development for the treatment of obesity, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in